Umoja wa Ulaya - Kifinlandi - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft hylkääminen - immunosuppressantit - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Umoja wa Ulaya - Kifinlandi - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - arseenitrioksidi - leukemia, promyelocytic, akuutti - antineoplastiset aineet - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. vastausprosentti muita akuutin myelooisen leukemian alatyyppien mukaan arseenitrioksidi ei ole tutkittu.

Umoja wa Ulaya - Kifinlandi - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosuppressantit - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Umoja wa Ulaya - Kifinlandi - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastiset aineet - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Ufini - Kifinlandi - Fimea (Suomen lääkevirasto)

fresenius kabi ab fresenius kabi ab - natrii chloridum,hydroxyethylcellulosum - infuusioneste, liuos - 100 mg/ml - hydroksietyylitärkkelys

Ufini - Kifinlandi - Fimea (Suomen lääkevirasto)

orion corporation - cinacalcet hydrochloride - tabletti, kalvopäällysteinen - 30 mg - sinakalseetti

Ufini - Kifinlandi - Fimea (Suomen lääkevirasto)

orion corporation - cinacalcet hydrochloride - tabletti, kalvopäällysteinen - 60 mg - sinakalseetti

Ufini - Kifinlandi - Fimea (Suomen lääkevirasto)

orion corporation - cinacalcet hydrochloride - tabletti, kalvopäällysteinen - 90 mg - sinakalseetti

Ufini - Kifinlandi - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - valsartanum,hydrochlorothiazidum,amlodipini besilas - tabletti, kalvopäällysteinen - 5 mg / 160 mg / 12.5 mg - valsartaani, amlodipiini ja hydroklooritiatsidi

Ufini - Kifinlandi - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - hydrochlorothiazidum,amlodipini besilas,valsartanum - tabletti, kalvopäällysteinen - 10 mg / 160 mg / 12.5 mg - valsartaani, amlodipiini ja hydroklooritiatsidi